A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 5, 2010, Pages 2497-2502

  Durán Prado, Mario ^a   Saveanu, Alexandru ^b,c   Luque, Raul M ^a   Gahete, Manuel D ^a   Gracia Navarro, Francisco ^a   Jaquet, Philippe ^b   Dufour, Henry ^d   Malagón, María M ^a   Culler, Michael D ^e   Barlier, Anne ^b,c   Castaño, Justo P ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b CNRS   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d TIMONE HOSPITAL   (France)

^e IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIM 23197; BIM 23268; GROWTH HORMONE; HORMONE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PROLACTIN; RECOMBINANT SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; SOMATOSTATIN RECEPTOR 5 TMD4; SOMATOSTATIN RECEPTOR 5 TMD5; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; OLIGOPEPTIDE; PIPERAZINE DERIVATIVE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR SUBTYPE 4; SOMATOSTATIN RECEPTOR SUBTYPE-4;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG POTENCY; DRUG SCREENING; FEMALE; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; ACROMEGALY; DRUG EFFECT; GENE DELETION; GENETIC VARIABILITY; GENETICS; HYPOPHYSIS TUMOR; POLYMERASE CHAIN REACTION;

ACROMEGALY; ANTINEOPLASTIC AGENTS, HORMONAL; GENETIC VARIATION; HUMANS; OCTREOTIDE; OLIGOPEPTIDES; PIPERAZINES; PITUITARY NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTORS, SOMATOSTATIN; SEQUENCE DELETION; SOMATOSTATIN;

EID: 77952763842     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2247     Document Type: Article

References (19)

1. Heaney AP, Melmed S 2004 Molecular targets in pituitary tumours. Nat Rev Cancer 4:285-295
2. Asa SL, Ezzat S 2009 The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97-126
3. Lamberts SW, Hofland LJ 2009 Future treatment strategies of aggressive pituitary tumors. Pituitary 12:261-264
4. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D 2007 Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592-1599
5. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S 2008 Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 93:1203-1210
6. Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR 2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65-74
7. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR 2008 Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 158:295-303
8. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017 (Pubitemid 37540581)
9. Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A 2008 Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 158:595-603
10. Bronstein MD 2006 Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res 35:129-134
11. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P 2001 Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86:140-145
12. Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-López P, Leal A, Schulz S, Gracia-Navarro F, Malagón MM, Castaño JP 2009 Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 94:2634-2643
13. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545-5552
14. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P 2006 Somatostatin and dopamine-somatostatin multiple ligands directed toward somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83:258-263
15. Kilpatrick GJ, Dautzenberg FM, Martin GR, Eglen RM 1999 7TM receptors: the splicing on the cake. Trends Pharmacol Sci 20:294-301
16. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A 1999 Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268-3276
17. Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U 2008 Cell Growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 22:2278-2292
18. Wilson CB 1984 A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg 61:814-833
19. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85:781-792